X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (24) 24
humans (23) 23
oncology (23) 23
adult (11) 11
female (10) 10
middle aged (10) 10
neoplastic meningitis (10) 10
breast cancer (9) 9
cancer (9) 9
chemotherapy (9) 9
clinical neurology (9) 9
metastasis (9) 9
survival (8) 8
aged (7) 7
leptomeningeal metastasis (7) 7
male (7) 7
brain metastases (6) 6
cerebrospinal-fluid (6) 6
diagnosis (6) 6
glioblastoma (6) 6
medicine & public health (6) 6
meningeal neoplasms - secondary (6) 6
prognostic-factors (6) 6
quality of life (6) 6
radiotherapy (6) 6
temozolomide (6) 6
tumors (6) 6
antineoplastic agents - therapeutic use (5) 5
bevacizumab (5) 5
brain cancer (5) 5
brain neoplasms - therapy (5) 5
breast neoplasms - pathology (5) 5
cancer therapies (5) 5
care and treatment (5) 5
hematology, oncology and palliative medicine (5) 5
leptomeningeal metastases (5) 5
nervous-system metastases (5) 5
neurology (5) 5
prognosis (5) 5
treatment outcome (5) 5
brain neoplasms - diagnosis (4) 4
brain neoplasms - drug therapy (4) 4
brain neoplasms - pathology (4) 4
brain tumors (4) 4
breast-cancer (4) 4
gliomas (4) 4
malignant glioma (4) 4
meningeal carcinomatosis (4) 4
patients (4) 4
phase-ii trial (4) 4
quality-of-life (4) 4
radiation therapy (4) 4
research (4) 4
risk factors (4) 4
solid tumors (4) 4
studies (4) 4
therapy (4) 4
610 medicine & health (3) 3
anaplastic glioma (3) 3
brain neoplasms - mortality (3) 3
brain neoplasms - secondary (3) 3
cancer-patients (3) 3
capecitabine (3) 3
circulating tumor-cells (3) 3
clinic for neurology (3) 3
clinical trials (3) 3
csf cytology (3) 3
disease-free survival (3) 3
follow-up studies (3) 3
glioma (3) 3
immunotherapy (3) 3
injections, spinal (3) 3
magnetic resonance imaging (3) 3
meningeal neoplasms - cerebrospinal fluid (3) 3
meningeal neoplasms - diagnosis (3) 3
metastases (3) 3
oncology, experimental (3) 3
randomized-trial (3) 3
targeted therapy (3) 3
young adult (3) 3
adjuvant (2) 2
aged, 80 and over (2) 2
analysis (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
bevacizumab plus irinotecan (2) 2
blood (2) 2
brain (2) 2
brain neoplasms - complications (2) 2
brain research (2) 2
breast neoplasms - drug therapy (2) 2
breast neoplasms - mortality (2) 2
cancer and oncology (2) 2
cancer och onkologi (2) 2
carcinoma (2) 2
cell lung-cancer (2) 2
cellsearch (2) 2
cellular biology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. e315 - e329
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. e330 - e340
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 64 - 71
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1700 - 1710
Summary Background Patients with advanced HER2-positive breast cancer frequently develop CNS metastases. The metastases that progress after brain radiotherapy... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CAPECITABINE | BIBW 2992 | EFFICACY | ONCOLOGY | MUTATIONS | ERBB FAMILY BLOCKER | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Vinblastine - therapeutic use | Brain Neoplasms - secondary | Breast Neoplasms - chemistry | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Brain Neoplasms - mortality | Antineoplastic Agents, Phytogenic - therapeutic use | Biomarkers, Tumor - antagonists & inhibitors | Republic of Korea | Antineoplastic Agents, Phytogenic - adverse effects | Brain Neoplasms - chemistry | Trastuzumab - therapeutic use | Biomarkers, Tumor - analysis | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease Progression | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Care and treatment | Breast cancer | Product development | Metastasis | Antineoplastic agents
Journal Article
Surgical Neurology International, ISSN 2229-5097, 10/2013, Volume 4, Issue 4, pp. S265 - S288
Leptomeningeal metastasis (LM) results from metastatic spread of cancer to the leptomeninges, giving rise to central nervous system dysfunction. Breast cancer,... 
tyrosine kinase inhibitors | Diagnostic tools | targeted therapy | leptomeningeal metastases | neoplastic meningitis | monoclonal antibody | solid tumors | Chemotherapy | Nuclear magnetic resonance--NMR | Cellular biology | Hematology | Leukemia | Melanoma | Cytotoxicity | Breast cancer | Histology | Radiation therapy | Cancer therapies | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 20, pp. 1954 - 1963
The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase... 
Medicine(all) | MEDICINE, GENERAL & INTERNAL | METHYLATION | PROGNOSTIC-FACTORS | PLUS IRINOTECAN | SINGLE-AGENT BEVACIZUMAB | RESPONSE ASSESSMENT | CLINICAL-TRIALS | PHASE-2 | QUALITY-OF-LIFE | RADIOTHERAPY | TEMOZOLOMIDE | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Glioblastoma - mortality | Lomustine - administration & dosage | Patient outcomes | Lomustine | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Glioblastoma multiforme | Methods | Medical research | Nuclear magnetic resonance--NMR | Brain cancer | Methylguanine | Glioblastoma | Clinical trials | Oncology | Cognition | Cancer therapies | Survival | Quality of life | Bevacizumab | O6-methylguanine-DNA methyltransferase | Studies | Brain research | DNA methylation | DNA methyltransferase | Cancer
Journal Article